Table 2.
Characteristic | Low Expression of AKR1C1 (n=541) | High Expression of AKR1C1 (n=542) | P-value |
---|---|---|---|
Age, median (IQR) | 58 (48, 68) | 58 (49, 66) | 0.778 |
Age, n (%) | 1.000 | ||
≤60 | 300 (55.5%) | 301 (55.5%) | |
>60 | 241 (44.5%) | 241 (44.5%) | |
T stage, n (%) | 0.083 | ||
T1 | 129 (23.9%) | 148 (27.4%) | |
T2 | 327 (60.7%) | 302 (55.8%) | |
T3 | 61 (11.3%) | 78 (14.4%) | |
T4 | 22 (4.1%) | 13 (2.4%) | |
N stage, n (%) | 0.530 | ||
N0 | 247 (46.9%) | 267 (49.7%) | |
N1 | 186 (35.3%) | 172 (32%) | |
N2 | 60 (11.4%) | 56 (10.4%) | |
N3 | 34 (6.5%) | 42 (7.8%) | |
M stage, n (%) | 0.914 | ||
M0 | 462 (97.7%) | 440 (98%) | |
M1 | 11 (2.3%) | 9 (2%) | |
Pathologic stage, n (%) | 0.732 | ||
Stage I | 84 (15.9%) | 97 (18.2%) | |
Stage II | 314 (59.5%) | 305 (57.3%) | |
Stage III | 120 (22.7%) | 122 (22.9%) | |
Stage IV | 10 (1.9%) | 8 (1.5%) | |
Histological type, n (%) | < 0.001 | ||
Infiltrating ductal carcinoma | 413 (86.8%) | 359 (71.7%) | |
Infiltrating lobular carcinoma | 63 (13.2%) | 142 (28.3%) | |
PR status, n (%) | < 0.001 | ||
Negative | 139 (27.3%) | 203 (38.7%) | |
Indeterminate | 2 (0.4%) | 2 (0.4%) | |
Positive | 368 (72.3%) | 320 (61%) | |
ER status, n (%) | < 0.001 | ||
Negative | 84 (16.5%) | 156 (29.7%) | |
Indeterminate | 2 (0.4%) | 0 (0%) | |
Positive | 424 (83.1%) | 369 (70.3%) | |
HER2 status, n (%) | 0.012 | ||
Negative | 253 (72.7%) | 305 (80.5%) | |
Indeterminate | 4 (1.1%) | 8 (2.1%) | |
Positive | 91 (26.1%) | 66 (17.4%) | |
Anatomic neoplasm subdivisions, n (%) | 0.171 | ||
Left | 293 (54.2%) | 270 (49.8%) | |
Right | 248 (45.8%) | 272 (50.2%) | |
Radiation therapy, n (%) | 0.184 | ||
No | 225 (46.2%) | 209 (41.8%) | |
Yes | 262 (53.8%) | 291 (58.2%) |